Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use
Latest Information Update: 10 Jan 2022
At a glance
- Drugs COVID-2019 vaccine-ImmunityBio (Primary) ; COVID-2019 vaccine-ImmunityBio (Primary) ; COVID-2019 vaccine-ImmunityBio (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors ImmunityBio
- 14 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment, because the sponsor has changed the development plans which is not for safety reasons.
- 02 Dec 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Mar 2022.
- 02 Dec 2021 Planned initiation date changed from 1 Jun 2021 to 1 Dec 2021.